Genetic association studies of glutamate, GABA and related genes in schizophrenia and bipolar disorder: A decade of advance

Neuroscience and Biobehavioral Reviews

Volumn 34, Issue 6, 2010, Pages 958-977

  Cherlyn, Suat Ying Tan ^a   Woon, Puay San ^a   Liu, Jian Jun ^b   Ong, Wei Yi ^c   Tsai, Guo Chuan ^d   Sim, Kang ^a  

^a INSTITUTE OF MENTAL HEALTH   (Singapore)

^b GENOME INSTITUTE OF SINGAPORE   (Singapore)

^c NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^d HARBOR UCLA MEDICAL CENTER   (United States)

Author keywords

Bipolar disorder; Glutamate; Glutamatergic; Schizophrenia

Indexed keywords

4 [2 AMINO 4 (METHYLTHIO)BUTYRYLAMINO] 2 THIABICYCLO[3.1.0]HEXANE 4,6 DICARBOXYLIC ACID 2,2 DIOXIDE; 4 AMINO 2 THIABICYCLO[3.1.0]HEXANE 4,6 DICARBOXYLIC ACID 2,2 DIOXIDE; 4 AMINOBUTYRIC ACID; 4 AMINOBUTYRIC ACID A RECEPTOR BETA2; 4 AMINOBUTYRIC ACID RECEPTOR; AMPA RECEPTOR; CLONAZEPAM; CLOZAPINE; DEXTRO SERINE; EXCITATORY AMINO ACID TRANSPORTER 1; EXCITATORY AMINO ACID TRANSPORTER 2; GLUTAMATE AMMONIA LIGASE; GLUTAMATE DECARBOXYLASE; GLUTAMATE RECEPTOR 1; GLUTAMIC ACID; HALOPERIDOL; IONOTROPIC RECEPTOR; KAINIC ACID RECEPTOR; LAMOTRIGINE; LITHIUM SALT; LORAZEPAM; METABOTROPIC RECEPTOR; METABOTROPIC RECEPTOR 3; METABOTROPIC RECEPTOR AGONIST; METABOTROPIC RECEPTOR ANTAGONIST; N [3 (4 FLUOROPHENYL) 3 (4 PHENYLPHENOXY)PROPYL]SARCOSINE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; OLANZAPINE; PLACEBO; UNINDEXED DRUG;

BIPOLAR DISORDER; CLINICAL TRIAL; DRUG EFFICACY; DRUG MECHANISM; EXTRAPYRAMIDAL SYMPTOM; GABAERGIC TRANSMISSION; GENE EXPRESSION; GENE LOCUS; GENETIC ASSOCIATION; GENETIC RISK; GENETIC SUSCEPTIBILITY; GENETIC TRANSCRIPTION; GENETIC VARIABILITY; HAPLOTYPE; HETEROZYGOTE; HUMAN; HYPERPROLACTINEMIA; NEUROPROTECTION; NONHUMAN; PRIORITY JOURNAL; PROMOTER REGION; REVIEW; RISK FACTOR; SCHIZOPHRENIA; SIDE EFFECT; SINGLE NUCLEOTIDE POLYMORPHISM; TRANQUILIZING ACTIVITY; WEIGHT GAIN;

ANIMALS; BIPOLAR DISORDER; GAMMA-AMINOBUTYRIC ACID; GENETIC ASSOCIATION STUDIES; GLUTAMIC ACID; HUMANS; SCHIZOPHRENIA; SYNAPTIC TRANSMISSION;

EID: 77950629668     PISSN: 01497634     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neubiorev.2010.01.002     Document Type: Review

References (268)

1. Addington A.M., Gornick M., Sporn A.L., Gogtay N., Greenstein D., Lenane M., Gochman P., Baker N., Balkissoon R., Vakkalanka R.K., Weinberger D.R., Straub R.E., Rapoport J.L. Polymorphisms in the 13q33.2 gene G72/G30 are associated with childhood-onset schizophrenia and psychosis not otherwise specified. Biol. Psychiatry 2004, 55:976-980.
2. Addington A.M., Gornick M., Duckworth J., Sporn A., Gogtay N., Bobb A., Greenstein D., Lenane M., Gochman P., Baker N., Balkissoon R., Vakkalanka R.K., Weinberger D.R., Rapoport J.L., Straub R.E. GAD1 (2q31.1), which encodes glutamic acid decarboxylase (GAD67), is associated with childhood-onset schizophrenia and cortical gray matter volume loss. Mol. Psychiatry 2005, 10:581-588.
3. Ahmad Y., Bhatia M.S., Mediratta P.K., Sharma K.K., Negi H., Chosdol K., Sinha S. Association between the ionotropic glutamate receptor kainate3 (GRIK3) Ser310Ala polymorphism and schizophrenia in the Indian population. World J. Biol. Psychiatry 2009, 23:1-4.
4. Ahnaou A., Dautzenberg F.M., Geys H., Imogai H., Gibelin A., Moechars D., Steckler T., Drinkenburg W.H.I.M. Modulation of group II metabotropic glutamate receptor (mGlu2) elicits common changes in rat and mice sleep-wake architecture. Eur. J. Pharmacol. 2009, 603:62-72.
5. Albalushi T., Horiuchi Y., Ishiguro H., Koga M., Inada T., Iwata N., Ozaki N., Ujike H., Watanabe Y., Someya T., Arinami T. Replication study and meta-analysis of the genetic association of GRM3 gene polymorphisms with schizophrenia in a large Japanese case-control population. Am. J. Med. Genet. B Neuropsychiatr. Genet. 2008, 147:392-396.
6. Aleman A., Kahn R.S., Selten J.-P. Sex differences in the risk of schizophrenia: evidence from meta-analysis. Arch. Gen. Psychiatry 2003, 60:565-571.
7. American Psychiatric Association, 2000. Diagnostic and Statistical Manual of Mental Disorders (fourth ed., text revision). APA, Washington, D.C.
8. Ann Van Den Bogaert J.D.-F.C.V.B. Major affective disorders and schizophrenia: a common molecular signature?. Hum. Mutat. 2006, 27:833-853.
9. Arai S., Shibata H., Sakai M., Ninomiya H., Iwata N., Ozaki N., Fukumaki Y. Association analysis of the glutamic acid decarboxylase 2 and the glutamine synthetase genes (GAD2, GLUL) with schizophrenia. Psychiatr. Genet. 2009, 19:6-13.
10. Arriza J.L., Kavanaugh M.P., Fairman W.A., Wu Y.N., Murdoch G.H., North R.A., Amara S.G. Cloning and expression of a human neutral amino acid transporter with structural similarity to the glutamate transporter gene family. J. Biol. Chem. 1993, 268:15329-15332.
11. Asada H., Kawamura Y., Maruyama K., Kume H., Ding R.-G., Kanbara N., Kuzume H., Sanbo M., Yagi T., Obata K. Cleft palate and decreased brain γ-aminobutyric acid in mice lacking the 67-kDa isoform of glutamic acid decarboxylase. Proc. Natl. Acad. Sci. U.S.A. 1997, 94:6496-6499.
12. Asada H., Kawamura Y., Maruyama K., Kume H., Ding R.-g., Ji F.Y., Kanbara N., Kuzume H., Sanbo M., Yagi T., Obata K. Mice lacking the 65 kDa isoform of glutamic acid decarboxylase (GAD65) maintain normal levels of GAD67 and GABA in their brains but are susceptible to seizures. Biochem. Biophys. Res. Commun. 1996, 229:891-895.
13. Austin J. Schizophrenia: an update and review. J. Genet. Counselling 2005, 14:329-340.
14. Badner J.A., Gershon E.S. Meta-analysis of whole-genome linkage scans of bipolar disorder and schizophrenia. Mol. Psychiatry 2002, 7:405-411.
15. Ballard T.M., Pauly-Evers M., Higgins G.A., Ouagazzal A.M., Mutel V., Borroni E., Kemp J.A., Bluethmann H., Kew J.N. Severe impairment of NMDA receptor function in mice carrying targeted point mutations in the glycine binding site results in drug-resistant nonhabituating hyperactivity. J. Neurosci. 2002, 22:6713-6723.
16. Bar-Peled O., Ben-Hur H., Biegon A., Groner Y., Dewhurst S., Furuta A. Distribution of glutamate transporter subtypes during human brain development. J. Neurochem. 1997, 69:2571-2580.
17. Begni S., Popoli M., Moraschi S., Bignotti S., Tura G.B., Gennarelli M. Association between the ionotropic glutamate receptor kainate 3 (GRIK3) ser310ala polymorphism and schizophrenia. Mol. Psychiatry 2002, 7:416-418.
18. Begni S., Moraschi S., Bignotti S., Fumagalli F., Rillosi L., Perez J., Gennarelli M. Association between the G1001C polymorphism in the GRIN1 gene promoter region and schizophrenia. Biol. Psychiatry 2003, 53:617-619.
19. Benazzi F. Bipolar disorder-focus on bipolar II disorder and mixed depression. Lancet 2007, 369:935-945.
20. Benes F.M., Todtenkopf M.S., Kostoulakos P. GluR567 subunit immunoreactivity on apical pyramidal cell dendrites in hippocampus of schizophrenics and manic depressives. Hippocampus 2001, 11:482-491.
21. Beneyto M., Kristiansen L.V., Oni-Orisan A., McCullumsmith R.E., Meador-Woodruff J.H. Abnormal glutamate receptor expression in the medial temporal lobe in schizophrenia and mood disorders. Neuropsychopharmacology 2007, 32:1888-1902.
22. Benzel I., Kew J., Viknaraja R., Kelly F., de Belleroche J., Hirsch S., Sanderson T., Maycox P. Investigation of G72 (DAOA) expression in the human brain. BMC Psychiatry 2008, 8:94.
23. Berrettini W.H., Ferraro T.N., Goldin L.R., Weeks D.E., Detera-Wadleigh S., Nurnberger J.I., Gershon E.S. Chromosome 18 DNA markers and manic-depressive illness: evidence for a susceptibility gene. Proc. Natl. Acad. Sci. U.S.A. 1994, 91:5918-5921.
24. Bhagwagar Z., Goodwin G.M. Lamotrigine in the treatment of bipolar disorder. Exp. Opin. Pharmacother. 2005, 6:1401-1408.
25. Biggio G., Brodie B.B., Costa E., Guidotti A. Mechanisms by which diazepam, muscimol, and other drugs change the content of cGMP in cerebellar cortex. Proc. Natl. Acad. Sci. U.S.A. 1977, 74:3592-3596.
26. Bishop J.R., Ellingrod V.L. Metabotrophic glutamate receptor genes as candidates for pharmaco-genetic studies of current and future antipyschotic agents in schizophrenia. Curr. Pharmacogenom. 2007, 5:21-30.
27. Bishop J.R., Ellingrod V.L., Moline J., Miller D. Association between the polymorphic GRM3 gene and negative symptom improvement during olanzapine treatment. Schizophr. Res. 2005, 77:253-260.
28. Bixler E.O., Kales A., Brubaker B.H., Kales J.D. Adverse reactions to benzodiazepine hypnotics: spontaneous reporting system. Pharmacology 1987, 35:286-300.
29. Blaise M.C., Bhattacharyya D., Sowdhamini R., Pradhan N. Structural consequences of D481N/K483Q mutation at glycine binding site of NMDA ionotropic glutamate receptors: a molecular dynamics study. J. Biomol. Struct. Dyn. 2005, 22:399-410.
30. Blouin J.L., Dombroski B.A., Nath S.K., Lasseter V.K., Wolyniec P.S., Nestadt G., Thornquist M., Ullrich G., McGrath J., Kasch L., Lamacz M., Thomas M.G., Gehrig C., Radhakrishna U., Snyder S.E., Balk K.G., Neufeld K., Swartz K.L., DeMarchi N., Papadimitriou G.N., Dikeos D.G., Stefanis C.N., Chakravarti A., Childs B., Housman D.E., Kazazian H.H., Antonarakis S., Pulver A.E. Schizophrenia susceptibility loci on chromosomes 13q32 and 8p21. Nat. Genet. 1998, 20:70-73.
31. Boin F., Zanardini R., Pioli R., Altamura C.A., Maes M., Gennarelli M. Association between -G308A tumor necrosis factor alpha gene polymorphism and schizophrenia. Mol. Psychiatry 2001, 6:79-82.
32. Bolonna A.A., Kerwin R.W., Munro J., Arranz M.J., Makoff A.J. Polymorphisms in the genes for mGluR types 7 and 8: association studies with schizophrenia. Schizophr. Res. 2001, 47:99-103.
33. Bowden C.L., Edwards S., Evoniuk G. Open-label, concomitant use of lamotrigine and other medications for bipolar disorder. CNS Spectrums 2008, 13:75-83.
34. Brené S., Messer C., Nestler E.J. Expression of messenger RNAs encoding ionotropic glutamate receptors in rat brain: regulation by haloperidol. Neuroscience 1998, 84:813-823.
35. Brodie M.J., McKee P.J. Vigabatrin and psychosis. Lancet 1990, 335:1279.
36. Brzustowicz L.M., Honer W.G., Chow E.W., Little D., Hogan J., Hodgkinson K., Bassett A.S. Linkage of familial schizophrenia to chromosome 13q32. Am. J. Hum. Genet. 1999, 65:1096-1103.
37. Carbonell L., Cuffí M.L., Forn J. Effect of chronic lithium treatment on the turnover of [alpha]2-adrenoceptors after chemical inactivation in rats. Eur. Neuropsychopharmacol. 2004, 14:497-502.
38. Chavez-Noriega L.E., Schaffhauser H., Campbell U.C. Metabotropic glutamate receptors: potential drug targets for the treatment of schizophrenia. Curr. Drug Targets CNS Neurol. Disord. 2002, 1:261-281.
39. Chen Q., He G., Wu S., Xu Y., Feng G., Li Y., Wang L., He L. A case-control study of the relationship between the metabotropic glutamate receptor 3 gene and schizophrenia in the Chinese population. Schizophr. Res. 2005, 73:21-26.
40. Chen Y.S., Akula N., Detera-Wadleigh S.D., Schulze T.G., Thomas J., Potash J.B., DePaulo J.R., McInnis M.G., Cox N.J., McMahon F.J. Findings in an independent sample support an association between bipolar affective disorder and the G72/G30 locus on chromosome 13q33. Mol. Psychiatry 2004, 9:87-92.
41. Chumakov I., Blumenfeld M., Guerassimenko O., Cavarec L., Palicio M., Abderrahim H., Bougueleret L., Barry C., Tanaka H., La Rosa P., Puech A., Tahri N., Cohen-Akenine A., Delabrosse S., Lissarrague S., Picard F.P., Maurice K., Essioux L., Millasseau P., Grel P., Debailleul V., Simon A.M., Caterina D., Dufaure I., Malekzadeh K., Belova M., Luan J.J., Bouillot M., Sambucy J.L., Primas G., Saumier M., Boubkiri N., Martin-Saumier S., Nasroune M., Peixoto H., Delaye A., Pinchot V., Bastucci M., Guillou S., Chevillon M., Sainz-Fuertes R., Meguenni S., Aurich-Costa J., Cherif D., Gimalac A., Van Duijn C., Gauvreau D., Ouellette G., Fortier I., Raelson J., Sherbatich T., Riazanskaia N., Rogaev E., Raeymaekers P., Aerssens J., Konings F., Luyten W., Macciardi F., Sham P.C., Straub R.E., Weinberger D.R., Cohen N., Cohen D. Genetic and physiological data implicating the new human gene G72 and the gene for D-amino acid oxidase in schizophrenia. Proc. Natl. Acad. Sci. U.S.A. 2002, 99:13675-13680.
42. Ciabarra A.M., Sullivan J.M., Gahn L.G., Pecht G., Heinemann S., Sevarino K.A. Cloning and characterization of χ-1: a developmentally regulated member of a novel class of the ionotropic glutamate receptor family. J. Neurosci. 1995, 15:6498-6508.
43. Clinton S.M., Meadow-Woodruff J.H. Abnormalities of the NMDA receptor and associated intracellular molecules in the thalamus in schizophrenia and bipolar disorder. Neuropsychopharmacology 2004, 29:1353-1362.
44. Conn P.J., Pin J.-P. Pharmacology and functions of metabotropic glutamate receptors. Annu. Rev. Pharmacol. Toxicol. 1997, 37:205-237.
45. Corti C., Crepaldi L., Mion S., Roth A.L., Xuereb J.H., Ferraguti F. Altered dimerization of metabotropic glutamate receptor 3 in schizophrenia. Biol. Psychiatry 2007, 62:747-755.
46. Corvin A., McGhee K.A., Murphy K., Donohoe G., Nangle J.M.S.S., Kenny N., Clarke S., Meagher D., Quinn J., Scully P., Baldwin P., Browne D., Walsh C., Waddington J.L., Morris D.W., Gill M. Evidence for association and epistasis at the DAOA/G30 and amino acid oxidase loci in an Irish schizophrenia sample. Am. J. Med. Genet. Part B: Neuropsychiatr. Genet. 2007, 144B:949-953.
47. Corvin A., McGhee K.A., Murphy K., Donohoe G., Nangle J.M., Schwaiger S., Kenny N., Clarke S., Meagher D., Quinn J., Scully P., Baldwin P., Browne D., Walsh C., Waddington J.L., Morris D.W., Gill M. Evidence for association and epistasis at the DAOA/G30 and D-amino acid oxidase loci in an Irish schizophrenia sample. Am. J. Med. Genet. B Neuropsychiatr. Genet. 2007, 144B:949-953.
48. Cosford N.D.P., Tehrani L., Roppe J., Schweiger E., Smith N.D., Anderson J., Bristow L., Brodkin J., Jiang X., McDonald I., Rao S., Washburn M., Varney M.A. 3-[(2-Methyl-1,3-thiazol-4-yl)ethynyl]-pyridine: a potent and highly selective metabotropic glutamate subtype 5 receptor antagonist with anxiolytic activity. J. Med. Chem. 2003, 46:204-206.
49. Coyle J.T., Guochuan T., Goff D.C. Ionotropic glutamate receptors as therapeutic targets in schizophrenia. Curr. Drug Targets-CNS Neurol. Disorders 2002, 1:183.
50. Craddock N., O'Donovan M.C., Owen M.J. Genes for schizophrenia and bipolar disorder? Implications for psychiatric nosology. Schizophr. Bull. 2006, 32:9-16.
51. Danbolt N.C. Glutamate uptake. Prog. Neurobiol. 2001, 65:1-105.
52. Das S., Sasaki Y.F., Rothe T., Premkumar L.S., Takasu M., Crandall J.E., Dikkes P., Conner D.A., Rayudu P.V., Cheung W., Chen H.S.V., Lipton S.A., Nakanishi N. Increased NMDA current and spine density in mice lacking the NMDA receptor subunit NR3A. Nature 1998, 393:377-381.
53. De Luca V., Muglia P., Masellis M., Jane Dalton E., Wong G.W., Kennedy J.L. Polymorphisms in glutamate decarboxylase genes: analysis in schizophrenia. Psychiatr. Genet. 2004, 14:39-42.
54. DeLisi L.E., Mesen A., Rodriguez C., Bertheau A., Laprade B., Llach M., Riondet S., Razi K., Relja M., Byerley W., Sherrington R. Genome-wide scan for linkage to schizophrenia in a Spanish-origin cohort from Costa Rica. Am. J. Med. Genet.-Neuropsychiatr. Genet. 2002, 114:497-508.
55. Deng X., Shibata H., Ninomiya H., Tashiro N., Iwata N., Ozaki N., Fukumaki Y. Association study of polymorphisms in the excitatory amino acid transporter 2 gene (SLC1A2) with schizophrenia. BMC Psychiatry 2004, 4:21.
56. Deng X., Shibata H., Takeuchi N., Rachi S., Sakai M., Ninomiya H., Iwata N., Ozaki N., Fukumaki Y. Association study of polymorphisms in the glutamate transporter genes SLC1A1, SLC1A3, and SLC1A6 with schizophrenia. Am. J. Med. Genet. B Neuropsychiatr. Genet. 2007, 144B:271-278.
57. Detera-Wadleigh S.D., McMahon F.J. G72/G30 in schizophrenia and bipolar disorder: review and meta-analysis. Biol. Psychiatry 2006, 60:106-114.
58. Devon R.S., Anderson S., Teague P.W., Muir W.J., Murray V., Pelosi A.J., Blackwood D.H., Porteous D.J. The genomic organisation of the metabotropic glutamate receptor subtype 5 gene, and its association with schizophrenia. Mol. Psychiatry 2001, 6:311-314.
59. Di Maria E., Gulli R., Begni S., De Luca A., Bignotti S., Pasini A., Bellone E., Pizzuti A., Dallapiccola B., Novelli G., Ajmar F., Gennarelli M., Mandich P. Variations in the NMDA receptor subunit 2B gene (GRIN2B) and schizophrenia: a case-control study. Am. J. Med. Genet. B Neuropsychiatr. Genet. 2004, 128B:27-29.
60. Dingledine R., Borges K., Bowie D., Traynelis S.F. The glutamate receptor ion channels. Pharmacol. Rev. 1999, 51:7-61.
61. Djurovic S., Kahler A.K., Kulle B., Jonsson E.G., Agartz I., Le Hellard S., Hall H., Jakobsen K.D., Hansen T., Melle I., Werge T., Steen V.M., Andreassen O.A. A possible association between schizophrenia and GRIK3 polymorphisms in a multicenter sample of Scandinavian origin (SCOPE). Schizophr. Res. 2009, 107:242-248.
62. Dracheva S., McGurk S.R., Haroutunian V. mRNA expression of AMPA receptors and AMPA receptor binding proteins in the cerebral cortex of elderly schizophrenics. J. Neurosci. Res. 2005, 79:868-878.
63. Du J., Suzuki K., Wei Y., Wang Y., Blumenthal R., Chen Z., Falke C., Zarate C.A., Manji H.K. The anticonvulsants lamotrigine, riluzole, and valproate differentially regulate AMPA receptor membrane localization: relationship to clinical effects in mood disorders. Neuropsychopharmacology 2007, 32:793-802.
64. Du J., Duan S., Wang H., Chen W., Zhao X., Zhang A., Wang L., Xuan J., Yu L., Wu S., Tang W., Li X., Li H., Feng G., Xing Q., He L. Comprehensive analysis of polymorphisms throughout GAD1 gene: a family-based association study in schizophrenia. J. Neural Transm. 2008, 115:513-519.
65. Egan M.F., Straub R.E., Goldberg T.E., Yakub I., Callicott J.H., Hariri A.R., Mattay V.S., Bertolino A., Hyde T.M., Shannon-Weickert C., Akil M., Crook J., Vakkalanka R.K., Balkissoon R., Gibbs R.A., Kleinman J.E., Weinberger D.R. Variation in GRM3 affects cognition, prefrontal glutamate, and risk for schizophrenia. Proc. Natl. Acad. Sci. U.S.A. 2004, 101:12604-12609.
66. Fallin M.D., Lasseter V.K., Avramopoulos D., Nicodemus K.K., Wolyniec P.S., McGrath J.A., Steel G., Nestadt G., Liang K.Y., Huganir R.L., Valle D., Pulver A.E. Bipolar I disorder and schizophrenia: a 440-single-nucleotide polymorphism screen of 64 candidate genes among Ashkenazi Jewish case-parent trios. Am. J. Hum. Genet. 2005, 77:918-936.
67. Faraone S.V., Matise T., Svrakic D., Pepple J., Malaspina D., Suarez B., Hampe C., Zambuto C.T., Schmitt K., Meyer J., Markel P., Lee H., Harkavy Friedman J., Kaufmann C., Cloninger C.R., Tsuang M.T. Genome scan of European-American schizophrenia pedigrees: results of the NIMH Genetics Initiative and Millennium Consortium. Am. J. Med. Genet. 1998, 81:290-295.
68. Fell M.J., Svensson K.A., Johnson B.G., Schoepp D.D. Evidence for the role of metabotropic glutamate (mGlu)2 not mGlu3 receptors in the preclinical antipsychotic pharmacology of the mGlu2/3 receptor agonist (-)-(1R,4S,5S,6S)-4-amino-2-sulfonylbicyclo[3.1.0]hexane-4,6-dicarboxylic acid (LY404039). J. Pharmacol. Exp. Ther. 2008, 326:209-217.
69. Foroud T., Castelluccio P.F., Koller D.L., Edenberg H.J., Miller M., Bowman E., Rau N.L., Smiley C., Rice J.P., Goate A., Armstrong C., Bierut L.J., Reich T., Detera-Wadleigh S.D., Goldin L.R., Badner J.A., Guroff J.J., Gershon E.S., McMahon F.J., Simpson S., MacKinnon D., McInnis M., Stine O.C., DePaulo J.R., Blehar M.C., Nurnberger J.I. Suggestive evidence of a locus on chromosome 10p using the NIMH genetics initiative bipolar affective disorder pedigrees. Am. J. Med. Genet. 2000, 96:18-23.
70. Fujii Y., Shibata H., Kikuta R., Makino C., Tani A., Hirata N., Shibata A., Ninomiya H., Tashiro N., Fukumaki Y. Positive associations of polymorphisms in the metabotropic glutamate receptor type 3 gene (GRM3) with schizophrenia. Psychiatr. Genet. 2003, 13:71-76.
71. Galehdari H., Pooryasin A., Foroughmand A., Daneshmand S., Saadat M. Association between the G1001C Polymorphism in the GRIN1 Gene Promoter and schizophrenia in the Iranian population. J. Mol. Neurosci. 2009, 38(2):178-181.
72. Galici R., Jones C.K., Hemstapat K., Nong Y., Echemendia N.G., Williams L.C., de Paulis T., Conn P.J. Biphenyl-indanone A, a positive allosteric modulator of the metabotropic glutamate receptor subtype 2, has antipsychotic- and anxiolytic-like effects in mice. J. Pharmacol. Exp. Ther. 2006, 318:173-185.
73. Ganda C., Schwab S.G., Amir N., Heriani H., Irmansyah I., Kusumawardhani A., Nasrun M., Widyawati I., Maier W., Wildenauer D.B. A family-based association study of DNA sequence variants in GRM7 with schizophrenia in an Indonesian population. Int. J. Neuropsychopharmacol. 2009, 12:1283-1289.
74. Georgi A., Jamra R.A., Schumacher J., Becker T., Schmael C., Deschner M., Höfels S., Wulff M., Schwarz M., Klopp N., Illig T., Propping P., Cichon S., Nöthen M.M., Rietschel M., Schulze T.G. No association between genetic variants at the GRIN1 gene and bipolar disorder in a German sample. Psychiatr. Genet. 2006, 16:183-184.
75. Ghose S., Crook J.M., Bartus C.L., Sherman T.G., Herman M.M., Hyde T.M., Kleinman J.E., Akil M. Metabotropic glutamate receptor 2 and 3 gene expression in the human prefrontal cortex and mesencephalon in schizophrenia. Int. J. Neurosci. 2008, 118:1609-1627.
76. Gill M., Vallada H., Collier D., Sham P., Holmans P., Murray R., McGuffin P., Nanko S., Owen M., Antonarakis S., Housman D., Kazazian H., Nestadt G., Pulver A.E., Straub R.E., MacLean C.J., Walsh D., Kendler K.S., DeLisi L., Polymeropoulos M., Coon H., Byerley W., Lofthouse R., Gershon E., Read C.M., et al. A combined analysis of D22S278 marker alleles in affected sib-pairs: support for a susceptibility locus for schizophrenia at chromosome 22q12. Schizophrenia Collaborative Linkage Group (Chromosome 22). Am. J. Med. Genet. 1996, 67:40-45.
77. Goetz T., Arslan A., Wisden W., Wulff P. GABA(A) receptors: structure and function in the basal ganglia. Prog. Brain Res. 2007, 160:21-41.
78. Goff D.C., Coyle J.T. The emerging role of glutamate in the pathophysiology and treatment of schizophrenia. Am. J. Psychiatry 2001, 158(9):1367-1377.
79. Goff D.C., Lamberti J.S., Leon A.C., Green M.F., Miller A.L., Patel J., Manschreck T., Freudenreich O., Johnson S.A. A placebo-controlled add-on trial of the Ampakine, CX516, for cognitive deficits in schizophrenia. Neuropsychopharmacology 2008, 33:465-472.
80. Goff D.C., Leahy L., Berman I., Posever T., Herz L., Leon A.C., Johnson S.A., Lynch G. A placebo-controlled pilot study of the ampakine CX516 added to clozapine in schizophrenia. J. Clin. Psychopharmacol. 2001, 21:484-487.
81. Gray L., van den Buuse M., Scarr E., Dean B., Hannan A.J. Clozapine reverses schizophrenia-related behaviours in the metabotropic glutamate receptor 5 knockout mouse: association with N-methyl-d-aspartic acid receptor up-regulation. Int. J. Neuropsychopharmacol. 2009, 12:45-60.
82. Green A.R., Vincent N.D. The effect of repeated electroconvulsive shock on GABA synthesis and release in regions of rat brain. Br. J. Pharmacol. 1987, 92:19-24.
83. Grimwood S., Slater P., Deakin J.F., Hutson P.H. NR2B-containing NMDA receptors are up-regulated in temporal cortex in schizophrenia. Neuroreport 1999, 10:461-465.
84. Gulli R., Masnata B., Bonvicini C., Tura G.B., Manglaviti L., Vaggi M., Mollica M., Bellone E., Mandich P., Gennarelli M., Di Maria E. A putative regulatory subunit (NR3A) of the NMDA receptor complex as candidate gene for susceptibility to schizophrenia: a case-control study. Psychiatr. Genet. 2007, 17:355-356.
85. Guo S., Shi Y., Zhao X., Duan S., Zhou J., Meng J., Yang Y., Gu N., Feng G., Liu H., Zhu S., He L. No genetic association between polymorphisms in the AMPA receptor subunit GluR4 gene (GRIA4) and schizophrenia in the Chinese population. Neurosci. Lett. 2004, 369:168-172.
86. Gupta D.S., McCullumsmith R.E., Beneyto M., Haroutunian V., Davis K.L., Meador-Woodruff J.H. Metabotropic glutamate receptor protein expression in the prefrontal cortex and striatum in schizophrenia. Synapse 2005, 57:123-131.
87. Gurling H.M., Kalsi G., Brynjolfson J., Sigmundsson T., Sherrington R., Mankoo B.S., Read T., Murphy P., Blaveri E., McQuillin A., Petursson H., Curtis D. Genomewide genetic linkage analysis confirms the presence of susceptibility loci for schizophrenia, on chromosomes 1q32.2, 5q33.2, and 8p21-22 and provides support for linkage to schizophrenia, on chromosomes 11q23.3-24 and 20q12.1-11.23. Am. J. Hum. Genet. 2001, 68:661-673.
88. Hall R.C., Zisook S. Paradoxical reactions to benzodiazepines. Br. J. Clin. Pharmacol. 1981, 11(Suppl. 1):99S-104S.
89. Harrison P.J., Owen M.J. Genes for schizophrenia? Recent findings and their pathophysiological implications. Lancet 2003, 361:417-419.
90. Harrison P.J., Weinberger D.R. Schizophrenia genes, gene expression, and neuropathology: on the matter of their convergence. Mol. Psychiatry 2005, 10:40-68.
91. Harrison P.J., Lyon L., Sartorius L.J., Burnet P., Lane T.A. Review: the group II metabotropic glutamate receptor 3 (mGluR3, mGlu3, GRM3): expression, function and involvement in schizophrenia. J. Psychopharmacol. 2008, 22:308-322.
92. Harvey B., Carstens M., Taljaard J. Lithium modulation of cortical cyclic nucleotides: evidence for the Yin-Yang hypothesis. Eur. J. Pharmacol. 1990, 175:129-136.
93. Hattori E., Liu C., Badner J.A., Bonner T.I., Christian S.L., Maheshwari M., Detera-Wadleigh S.D., Gibbs R.A., Gershon E.S. Polymorphisms at the G72/G30 gene locus, on 13q33, are associated with bipolar disorder in two independent pedigree series. Am. J. Hum. Genet. 2003, 72:1131-1140.
94. Healy D., Harris M., Farquhar F., Tschinkel S., Le Noury J. Historical overview: Kraepelin's impact on psychiatry. Eur. Arch. Psychiatry Clin. Neurosci. 2008, 258:18-24.
95. Healy D.J., Meador-Woodruff J.H. Clozapine and haloperidol differentially affect AMPA and kainate receptor subunit mRNA levels in rat cortex and striatum. Mol. Brain Res. 1997, 47:331-338.
96. Hernandez T.D., Gallager D.W. Development of long-term subsensitivity to GABA in dorsal raphe neurons of amygdala-kindled rats. Brain Res. 1992, 582:221-225.
97. Hernandez T.D., Rosen J.B., Gallager D.W. Long-term changes in sensitivity to GABA in dorsal raphe neurons following amygdala kindling. Brain Res. 1990, 517:294-300.
98. Hoehn-Saric R. Effects of THIP on chronic anxiety. Psychopharmacology (Berl) 1983, 80:338-341.
99. Hollmann M., Heinemann S. Cloned glutamate receptors. Annu. Rev. Neurosci. 1994, 17:31-108.
100. Hong C.J., Yu Y.W., Lin C.H., Cheng C.Y., Tsai S.J. Association analysis for NMDA receptor subunit 2B (GRIN2B) genetic variants and psychopathology and clozapine response in schizophrenia. Psychiatr. Genet. 2001, 11:219-222.
101. Hong C.J., Hou S.J., Yen F.C., Liou Y.J., Tsai S.J. Family-based association study between G72/G30 genetic polymorphism and schizophrenia. Neuroreport 2006, 17:1067-1069.
102. Hong C.J., Liou Y.J., Liao D.L., Hou S.J., Yen F.C., Tsai S.J. Association study of polymorphisms in the mitochondrial aspartate/glutamate carrier SLC25A12 (aralar) gene with schizophrenia. Prog. Neuropsychopharmacol. Biol. Psychiatry 2007, 31:1510-1513.
103. Ikeda M., Ozaki N., Yamanouchi Y., Suzuki T., Kitajima T., Kinoshita Y., Inada T., Iwata N. No association between the glutamate decarboxylase 67 gene (GAD1) and schizophrenia in the Japanese population. Schizophr. Res. 2007, 91:22-26.
104. Ikeda M., Iwata N., Suzuki T., Kitajima T., Yamanouchi Y., Kinoshita Y., Inada T., Ujike H., Ozaki N. Association analysis of chromosome 5 GABAA receptor cluster in Japanese schizophrenia patients. Biol. Psychiatry 2005, 58:440-445.
105. Itokawa M., Yamada K., Yoshitsugu K., Toyota T., Suga T., Ohba H., Watanabe A., Hattori E., Shimizu H., Kumakura T., Ebihara M., Meerabux J.M.A., Toru M., Yoshikawa T. A microsatellite repeat in the promoter of the N-methyl-D-aspartate receptor 2A subunit (GRIN2A) gene suppresses transcriptional activity and correlates with chronic outcome in schizophrenia. Pharmacogenetics 2003, 13:271-278.
106. Iwayama-Shigeno Y., Yamada K., Itokawa M., Toyota T., Meerabux J.M., Minabe Y., Mori N., Inada T., Yoshikawa T. Extended analyses support the association of a functional (GT)n polymorphism in the GRIN2A promoter with Japanese schizophrenia. Neurosci. Lett. 2005, 378:102-105.
107. Javitt D.C., Zukin S.R. Recent advances in the phencyclidine model of schizophrenia. Am. J. Psychiatry 1991, 148:1301-1308.
108. Joo A., Shibata H., Ninomiya H., Kawasaki H., Tashiro N., Fukumaki Y. Structure and polymorphisms of the human metabotropic glutamate receptor type 2 gene (GRM2): analysis of association with schizophrenia. Mol. Psychiatry 2001, 6:186-192.
109. Kamphuis W., Huisman E., Wadman W.J., Lopes da Silva F.H. Decrease in GABA immunoreactivity and alteration of GABA metabolism after kindling in the rat hippocampus. Exp. Brain Res. 1989, 74:375-386.
110. Kanai Y., Smith C.P., Hediger M.A. A new family of neurotransmitter transporters: the high-affinity glutamate transporters. FASEB J. 1993, 7:1450-1459.
111. Kaneva R., Milanova V., Angelicheva D., MacGregor S., Kostov C., Vladimirova R., Aleksiev S., Angelova M., Stoyanova V., Loh A., Hallmayer J., Kalaydjieva L., Jablensky A. Bipolar disorder in the Bulgarian Gypsies: genetic heterogeneity in a young founder population. Am. J. Med. Genet. B Neuropsychiatr. Genet. 2009, 150B:191-201.
112. Kapoor R., Lim K.S., Cheng A., Garrick T., Kapoor V. Preliminary evidence for a link between schizophrenia and NMDA-glycine site receptor ligand metabolic enzymes, d-amino acid oxidase (DAAO) and kynurenine aminotransferase-1 (KAT-1). Brain Res. 2006, 1106:205-210.
113. Kapur J., Stringer J.L., Lothman E.W. Evidence that repetitive seizures in the hippocampus cause a lasting reduction of GABAergic inhibition. J. Neurophysiol. 1989, 61:417-426.
114. Kelsoe J.R., Spence M.A., Loetscher E., Foguet M., Sadovnick A.D., Remick R.A., Flodman P., Khristich J., Mroczkowski-Parker Z., Brown J.L., Masser D., Ungerleider S., Rapaport M.H., Wishart W.L., Luebbert H. A genome survey indicates a possible susceptibility locus for bipolar disorder on chromosome 22. Proc. Natl. Acad. Sci. U.S.A. 2001, 98:585-590.
115. Kim J.S., Kornhuber H.H., Schmid-Burgk W., Holzmuller B. Low cerebrospinal fluid glutamate in schizophrenic patients and a new hypothesis on schizophrenia. Neurosci. Lett. 1980, 20:379-382.
116. Kornhuber J. Glutamate and schizophrenia. Trends Pharmacol. Sci. 1990, 11:357-1357.
117. Kornhuber J. Phencyclidine and schizophrenia. Am. J. Psychiatry 1992, 149:848-849.
118. Korostishevsky M., Kaganovich M., Cholostoy A., Ashkenazi M., Ratner Y., Dahary D., Bernstein J., Bening-Abu-Shach U., Ben-Asher E., Lancet D., Ritsner M., Navon R. Is the G72/G30 locus associated with schizophrenia? Single nucleotide polymorphisms, haplotypes, and gene expression analysis. Biol. Psychiatry 2004, 56:169-176.
119. Korostishevsky M., Kremer I., Kaganovich M., Cholostoy A., Murad I., Muhaheed M., Bannoura I., Rietschel M., Dobrusin M., Bening-Abu-Shach U., Belmaker R.H., Maier W., Ebstein R.P., Navon R. Transmission disequilibrium and haplotype analyses of the G72/G30 locus: suggestive linkage to schizophrenia in Palestinian Arabs living in the North of Israel. Am. J. Med. Genet. B Neuropsychiatr. Genet. 2006, 141B:91-95.
120. Krivoy A., Fischel T., Weizman A. The possible involvement of metabotropic glutamate receptors in schizophrenia. Eur. Neuropsychopharmacol. 2008, 18:395-405.
121. Krystal J.H., Karper L.P., Seibyl J.P., Freeman G.K., Delaney R., Bremner J.D., Heninger G.R., Bowers M.B., Charney D.S. Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans. Psychotomimetic, perceptual, cognitive, and neuroendocrine responses. Arch. Gen. Psychiatry 1994, 51:199-214.
122. Kvajo M., Dhilla A., Swor D.E., Karayiorgou M., Gogos J.A. Evidence implicating the candidate schizophrenia/bipolar disorder susceptibility gene G72 in mitochondrial function. Mol. Psychiatry 2008, 13:685-696.
123. Labrie V., Lipina T., Roder J.C. Mice with reduced NMDA receptor glycine affinity model some of the negative and cognitive symptoms of schizophrenia. Psychopharmacology (Berl) 2008, 200:217-230.
124. Labrie V., Clapcote S.J., Roder J.C. Mutant mice with reduced NMDA-NR1 glycine affinity or lack of D-amino acid oxidase function exhibit altered anxiety-like behaviors. Pharmacol. Biochem. Behav. 2009, 91:610-620.
125. Lahti A.C., Koffel B., LaPorte D., Tamminga C.A. Subanesthetic doses of ketamine stimulate psychosis in schizophrenia. Neuropsychopharmacology 1995, 13:9-19.
126. Lai I.C., Liou Y.J., Chen J.Y., Wang Y.C. No association between the ionotropic glutamate receptor kainate 3 gene ser310ala polymorphism and schizophrenia. Neuropsychobiology 2005, 51:211-213.
127. Law A.J., Deakin J.F.W. Asymmetrical reductions of hippocampal NMDARI glutamate receptor mRNA in the psychoses. Neuroreport 2001, 12:2971-2974.
128. Le Corre S., Harper C.G., Lopez P., Ward P., Catts S. Increased levels of expression of an NMDAR1 splice variant in the superior temporal gyrus in schizophrenia. NeuroReport 2000, 11:983-986.
129. Leahy R.L. Bipolar disorder: causes, contexts, and treatments. J. Clin. Psychol. 2007, 63:417-424.
130. Lee B.D., Walss-Bass C., Thompson P.M., Dassori A., Montero P.A., Medina R., Contreras S., Armas R., Ramirez M., Pereira M., Salazar R., Leach R.J., Quezada P., Raventos H., Escamilla M.A. Malic enzyme 2 and susceptibility to psychosis and mania. Psychiatry Res. 2007, 150:1-11.
131. Levine J., Panchalingam K., Rapoport A., Gershon S., McClure R.J., Pettegrew J.W. Increased cerebrospinal fluid glutamine levels in depressed patients. Biol. Psychiatry 2000, 47:586-593.
132. Lewin E., Peris J., Bleck V., Zahniser N.R., Harris R.A. Chemical kindling decreases GABA-activated chloride channels of mouse brain. Eur. J. Pharmacol. 1989, 160:101-106.
133. Lewis C.M., Levinson D.F., Wise L.H., et al. Genome scan meta-analysis of schizophrenia and bipolar disorder, part II: schizophrenia. Am. J. Hum. Genet. 2003, 73:34-48.
134. Li D., He L. G72/G30 genes and schizophrenia: a systematic meta-analysis of association studies. Genetics 2007, 175:917-922.
135. Li D., Lin H. Association study between the NMDA receptor 2B subunit gene (GRIN2B) and schizophrenia: a HuGE reveiw and meta-analysis. Genet. Med. 2007, 9:4-8.
136. Lin M.W., Sham P., Hwu H.G., Collier D., Murray R., Powell J.F. Suggestive evidence for linkage of schizophrenia to markers on chromosome 13 in Caucasian but not Oriental populations. Hum. Genet. 1997, 99:417-420.
137. Liu Y.L., Fann C.S., Liu C.M., Chang C.C., Wu J.Y., Hung S.I., Liu S.K., Hsieh M.H., Hwang T.J., Chan H.Y., Chen J.J., Faraone S.V., Tsuang M.T., Chen W.J., Hwu H.G. No association of G72 and D-amino acid oxidase genes with schizophrenia. Schizophr. Res. 2006, 87:15-20.
138. Liu J., Shi Y., Tang W., Guo T., Li D., Yang Y., Zhao X., Wang H., Li X., Feng G., Gu N., Zhu S., Liu H., Guo Y., Shi J., Sang H., Yan L., He L. Positive association of the human GABA-A-receptor beta 2 subunit gene haplotype with schizophrenia in the Chinese Han population. Biochem. Biophys. Res. Commun. 2005, 334:817-823.
139. Liu X., He G., Wang X., Chen Q., Qian X., Lin W., Li D., Gu N., Feng G., He L. Association of DAAO with schizophrenia in the Chinese population. Neurosci. Lett. 2004, 369:228-233.
140. Lo W.S., Lau C.F., Xuan Z., Chan C.F., Feng G.Y., He L., Cao Z.C., Liu H., Luan Q.M., Xue H. Association of SNPs and haplotypes in GABAA receptor beta2 gene with schizophrenia. Mol. Psychiatry 2004, 9:603-608.
141. Lo W.S., Harano M., Gawlik M., Yu Z., Chen J., Pun F.W., Tong K.L., Zhao C., Ng S.K., Tsang S.Y., Uchimura N., Stober G., Xue H. GABRB2 association with schizophrenia: commonalities and differences between ethnic groups and clinical subtypes. Biol. Psychiatry 2007, 61:653-660.
142. Lynch G. AMPA receptor modulators as cognitive enhancers. Curr. Opin. Pharm. 2004, 4:4-11.
143. Lynch G. Glutamate-based therapeutic approaches: Ampakines. Curr. Opin. Pharm. 2006, 6:82-88.
144. Lyon L., Kew J.N.C., Corti C., Harrison P.J., Burnet P.W.J. Altered hippocampal expression of glutamate receptors and transporters in GRM2 and GRM3 knockout mice. Synapse 2008, 62:842-850.
145. Ma J., Qin W., Wang X.Y., Guo T.W., Bian L., Duan S.W., Li X.W., Zou F.G., Fang Y.R., Fang J.X., Feng G.Y., Gu N.F., St Clair D., He L. Further evidence for the association between G72/G30 genes and schizophrenia in two ethnically distinct populations. Mol. Psychiatry 2006, 11:479-487.
146. Madeira C., Freitas M.E., Vargas-Lopes C., Wolosker H., Panizzutti R. Increased brain D-amino acid oxidase (DAAO) activity in schizophrenia. Schizophr. Res. 2008, 101:76-83.
147. Magri C., Gardella R., Barlati S.D., Podavini D., Iatropoulos P., Bonomi S., Valsecchi P., Sacchetti E., Barlati S. Glutamate AMPA receptor subunit 1 gene (GRIA1) and DSM-IV-TR schizophrenia: a pilot case-control association study in an Italian sample. Am. J. Med. Genet. B Neuropsychiatr. Genet. 2006, 141B:287-293.
148. Magri C., Gardella R., Valsecchi P., Barlati S.D., Guizzetti L., Imperadori L., Bonvicini C., Tura G.B., Gennarelli M., Sacchetti E., Barlati S. Study on GRIA2, GRIA3 and GRIA4 genes highlights a positive association between schizophrenia and GRIA3 in female patients. Am. J. Med. Genet. B Neuropsychiatr. Genet. 2008, 147B:745-753.
149. Maheshwari M., Shi J., Badner J.A., Skol A., Willour V.L., Muzny D.M., Wheeler D.A., Gerald F.R., Detera-Wadleigh S., McMahon F.J., Potash J.B., Gershon E.S., Liu C., Gibbs R.A. Common and rare variants of DAOA in bipolar disorder. Am. J. Med. Genet. B Neuropsychiatr. Genet. 2009, 150B:960-966.
150. Maier W. Common risk genes for affective and schizophrenic psychoses. Eur. Arch. Psychiatry Clin. Neurosci. 2008, 258(Suppl. 2):37-40.
151. Maier W., Hofgen B., Zobel A., Rietschel M. Genetic models of schizophrenia and bipolar disorder: overlapping inheritance or discrete genotypes?. Eur. Arch. Psychiatry Clin. Neurosci. 2005, 255:159-166.
152. Maiese K., Vincent A., Lin S.H., Shaw T. Group I and group III metabotropic glutamate receptor subtypes provide enhanced neuroprotection. J. Neurosci. Res. 2000, 62:257-272.
153. Makino C., Fujii Y., Kikuta R., Hirata N., Tani A., Shibata A., Ninomiya H., Tashiro N., Shibata H., Fukumaki Y. Positive association of the AMPA receptor subunit GluR4 gene (GRIA4) haplotype with schizophrenia: linkage disequilibrium mapping using SNPs evenly distributed across the gene region. Am. J. Med. Genet. B Neuropsychiatr. Genet. 2003, 116B:17-22.
154. Makino C., Shibata H., Ninomiya H., Tashiro N., Fukumaki Y. Identification of single-nucleotide polymorphisms in the human N-methyl-D-aspartate receptor subunit NR2D gene, GRIN2D, and association study with schizophrenia. Psychiatr. Genet. 2005, 15:215-221.
155. Maragakis N.J., Rothstein J.D. Glutamate transporters in neurologic disease. Arch. Neurol. 2001, 58:365-370.
156. Marti S.B., Cichon S., Propping P., Nothen M. Metabotropic glutamate receptor 3 (GRM3) gene variation is not associated with schizophrenia or bipolar affective disorder in the German population. Am. J. Med. Genet. 2002, 114:46-50.
157. Martucci L., Wong A.H., De Luca V., Likhodi O., Wong G.W., King N., Kennedy J.L. N-methyl-D-aspartate receptor NR2B subunit gene GRIN2B in schizophrenia and bipolar disorder: Polymorphisms and mRNA levels. Schizophr. Res. 2006, 84:214-221.
158. Martucci L., Wong A.H., Trakalo J., Cate-Carter T., Wong G.W., Macciardi F.M., Kennedy J.L. N-methyl-D-aspartate receptor NR1 subunit gene (GRIN1) in schizophrenia: TDT and case-control analyses. Am. J. Med. Genet. B Neuropsychiatr. Genet. 2003, 119B:24-27.
159. Masson J., Sagne C., Hamon M., El Mestikawy S. Neurotransmitter transporters in the central nervous system. Pharmacol. Rev. 1999, 51:439-464.
160. Mattsson H. Bicyclic phosphates increase the cyclic GMP level in rat cerebellum, presumably due to reduced GABA inhibition. Brain Res. 1980, 181:175-184.
161. Matute C., Melone M., Vallejo-Illarramendi A., Conti F. Increased expression of the astrocytic glutamate transporter GLT-1 in the prefrontal cortex of schizophrenics. Glia 2005, 49:451-455.
162. McCullumsmith R.E., Meador-Woodruff J.H. Striatal excitatory amino acid transporter transcript expression in schizophrenia, bipolar disorder, and major depressive disorder. Neuropsychopharmacology 2002, 26:368-375.
163. McCullumsmith R.E., Kristiansen L.V., Beneyto M., Scarr E., Dean B., Meador-Woodruff J.H. Decreased NR1, NR2A, and SAP102 transcript expression in the hippocampus in bipolar disorder. Brain Res. 2007, 1127:108-118.
164. Meador-Woodruff J.H., Healy D.J. Glutamate receptor expression in schizophrenic brain. Brain Res. Rev. 2000, 31:288-294.
165. Meador-Woodruff J.H., Davis K.L., Haroutunian V. Abnormal kainate receptor expression in prefrontal cortex in schizophrenia. Neuropsychopharmacology 2001, 24:545-552.
166. Meador-Woodruff J.H., King R.E., Damask S.P., Bovenkerk K.A. Differential regulation of hippocampal AMPA and kainate receptor subunit expression by haloperidol and clozapine. Mol. Psychiatry 1996, 1:41-53.
167. Melone M., Bragina L., Conti F. Clozapine-induced reduction of glutamate transport in the frontal cortex is not mediated by GLAST and EAAC1. Mol. Psychiatry 2003, 8:12-13.
168. Melone M., Vitellaro-Zuccarello L., Vallejo-Illarramendi A., Perez-Samartin A., Matute C., Cozzi A., Pellegrini-Giampietro D.E., Rothstein J.D., Conti F. The expression of glutamate transporter GLT-1 in the rat cerebral cortex is down-regulated by the antipsychotic drug clozapine. Mol. Psychiatry 2001, 6:380-386.
169. Michels G., Moss S.J. GABA A receptors: properties and trafficking. Crit. Rev. Biochem. Mol. Biol. 2007, 42:3-14.
170. Miyatake R., Furukawa A., Suwaki H. Identification of a novel variant of the human NR2B gene promoter region and its possible association with schizophrenia. Mol. Psychiatry 2002, 7:1101-1106.
171. Moghaddam B., Adams B.W. Reversal of phencyclidine effects by a group II metabotropic glutamate receptor agonist in rats. Science 1998, 281:1349-1352.
172. Moghaddam B., Adams B., Verma A., Daly D. Activation of glutamatergic neurotransmission by ketamine: a novel step in the pathway from NMDA receptor blockade to dopaminergic and cognitive disruptions associated with the prefrontal cortex. J. Neurosci. 1997, 17:2921-2927.
173. Mohn A.R., Gainetdinov R.R., Caron M.G., Koller B.H. Mice with reduced NMDA receptor expression display behaviors related to schizophrenia. Cell 1999, 98:427-436.
174. Molina V., Sánchez J., Sanz J., Reig S., Benito C., Leal I., Sarramea F., Rebolledo R., Palomo T., Desco M. Dorsolateral prefrontal N-acetyl-aspartate concentration in male patients with chronic schizophrenia and with chronic bipolar disorder. Eur. Psychiatry 2007, 22:505-512.
175. Mossner R., Schuhmacher A., Schulze-Rauschenbach S., Kuhn K.U., Rujescu D., Rietschel M., Zobel A., Franke P., Wolwer W., Gaebel W., Hafner H., Wagner M., Maier W. Further evidence for a functional role of the glutamate receptor gene GRM3 in schizophrenia. Eur. Neuropsychopharmacol. 2008, 18:768-772.
176. Mueller H.T., Meador-Woodruff J.H. NR3A NMDA receptor subunit mRNA expression in schizophrenia, depression and bipolar disorder. Schizophr. Res. 2004, 71:361-370.
177. Mueller H.T., Haroutunian V., Davis K.L., Meador-Woodruff J.H. Expression of the ionotropic glutamate receptor subunits and NMDA receptor-associated intracellular proteins in the substantia nigra in schizophrenia. Mol. Brain Res. 2004, 121:60-69.
178. Muesser K.T., McGurk S.R. Schizophrenia. Lancet 2004, 363:2063-2072.
179. Müller-Oerlinghausen B., Berghöfer A., Bauer M. Bipolar disorder. Lancet 2002, 359:241-247.
180. Mulle J.G., Chowdari K.V., Nimgaonkar V., Chakravarti A. No evidence for association to the G72/G30 locus in an independent sample of schizophrenia families. Mol. Psychiatry 2005, 10:431-433.
181. Munafò M.R., Thiselton D.L., Clark T.G., Flint J. Association of the NRG1 gene and schizophrenia: a meta-analysis. Mol. Psychiatry 2006, 11(June (6)):539-546.
182. Mundo E., Tharmalingham S., Neves-Pereira M., Dalton E.J., Macciardi F., Parikh S.V., Bolonna A., Kerwin R.W., Arranz M.J., Makoff A.J., Kennedy J.L. Evidence that the N-methyl-D-aspartate subunit 1 receptor gene (GRIN1) confers susceptibility to bipolar disorder. Mol. Psychiatry. 2003, 8:241-245.
183. Nicodemus K., Kolachana B., Vakkalanka R., Straub R., Giegling I., Egan M., Rujescu D., Weinberger D. Evidence for statistical epistasis between catechol-O-methyltransferase (COMT) and polymorphisms in RGS4, G72 (DAOA), GRM3, and DISC1: influence on risk of schizophrenia. Hum. Genet. 2007, 120:889-906.
184. Norton N., Williams H.J., Dwyer S., Ivanov D., Preece A.C., Gerrish A., Williams N.M., Yerassimou P., Zammit S., O'Donovan M.C., Owen M.J. No evidence for association between polymorphisms in GRM3 and schizophrenia. BMC Psychiatry 2005, 5:23.
185. Nudmamud-Thanoi S., Reynolds G.P. The NR1 subunit of the glutamate/NMDA receptor in the superior temporal cortex in schizophrenia and affective disorders. Neurosci. Lett. 2004, 372:173-177.
186. O'Connor J.A., Hemby S.E. Elevated GRIA1 mRNA expression in Layer II/III and V pyramidal cells of the DLPFC in schizophrenia. Schizophr. Res. 2007, 97:277-288.
187. O'Connor J.A., Muly E.C., Arnold S.E., Hemby S.E. AMPA receptor subunit and splice variant expression in the DLPFC of schizophrenic subjects and rhesus monkeys chronically administered antipsychotic drugs. Schizophr. Res. 2007, 90:28-40.
188. O'Neill L.A., Kaltschmidt C. NF-kappa B: a crucial transcription factor for glial and neuronal cell function. Trends Neurosci. 1997, 20:252-258.
189. Ohnuma T., Tessler S., Arai H., Faull R.L., McKenna P.J., Emson P.C. Gene expression of metabotropic glutamate receptor 5 and excitatory amino acid transporter 2 in the schizophrenic hippocampus. Brain Res. Mol. Brain Res. 2000, 85:24-31.
190. Ohtsuki T., Sakurai K., Dou H., Toru M., Yamakawa-Kobayashi K., Arinami T. Mutation analysis of the NMDAR2B (GRIN2B) gene in schizophrenia. Mol. Psychiatry 2001, 6:211-216.
191. Ohtsuki T., Koga M., Ishiguro H., Horiuchi Y., Arai M., Niizato K., Itokawa M., Inada T., Iwata N., Iritani S., Ozaki N., Kunugi H., Ujike H., Watanabe Y., Someya T., Arinami T. A polymorphism of the metabotropic glutamate receptor mGluR7 (GRM7) gene is associated with schizophrenia. Schizophr. Res. 2008, 101:9-16.
192. Opgen-Rhein C., Lencz T., Burdick K.E., Neuhaus A.H., DeRosse P., Goldberg T.E., Malhotra A.K. Genetic variation in the DAOA gene complex: impact on susceptibility for schizophrenia and on cognitive performance. Schizophr. Res. 2008, 103:169-177.
193. Otte D.M., Bilkei-Gorzó A., Filiou M.D., Turck C.W., Yilmaz O., Holst M.I., Schilling K., Abou-Jamra R., Schumacher J., Benzel I., Kunz W.S., Beck H., Zimmer A. Behavioral changes in G72/G30 transgenic mice. Eur. Neuropsychopharmacol. 2009, 19:339-348.
194. Palucha A., Tatarczylska E., Bralski P., Szewczyk B., Wierolska J.M., Klak K., Chojnacka-Wójcik E., Nowak G., Pilc A. Group III mGlu receptor agonists produce anxiolytic- and antidepressant-like effects after central administration in rats. Neuropharmacology 2004, 46:151-159.
195. Patil S.T., Zhang L., Martenyi F., Lowe S.L., Jackson K.A., Andreev B.V., Avedisova A.S., Bardenstein L.M., Gurovich I.Y., Morozova M.A., Mosolov S.N., Neznanov N.G., Reznik A.M., Smulevich A.B., Tochilov V.A., Johnson B.G., Monn J.A., Schoepp D.D. Activation of mGlu2/3 receptors as a new approach to treat schizophrenia: a randomized Phase 2 clinical trial. Nat. Med. 2007, 13(9):1102-1107.
196. Paunio T., Ekelund J., Varilo T., Parker A., Hovatta I., Turunen J.A., Rinard K., Foti A., Terwilliger J.D., Juvonen H., Suvisaari J., Arajarvi R., Suokas J., Partonen T., Lonnqvist J., Meyer J., Peltonen L. Genome-wide scan in a nationwide study sample of schizophrenia families in Finland reveals susceptibility loci on chromosomes 2q and 5q. Hum. Mol. Genet. 2001, 10:3037-3048.
197. Perlis R.H., Purcell S., Fagerness J., Kirby A., Petryshen T.L., Fan J., Sklar P. Family-based association study of lithium-related and other candidate genes in bipolar disorder. Arch. Gen. Psychiatry 2008, 65:53-61.
198. Petersen R.C., Stillman R.C. Phencyclidine: an overview. NIDA Res. Monogr. 1978, 1-17.
199. Petryshen T.L., Middleton F.A., Tahl A.R., Rockwell G.N., Purcell S., Aldinger K.A., Kirby A., Morley C.P., McGann L., Gentile K.L., Waggoner S.G., Medeiros H.M., Carvalho C., Macedo A., Albus M., Maier W., Trixler M., Eichhammer P., Schwab S.G., Wildenauer D.B., Azevedo M.H., Pato M.T., Pato C.N., Daly M.J., Sklar P. Genetic investigation of chromosome 5q GABAA receptor subunit genes in schizophrenia. Mol. Psychiatry 2005, 10:1074-1088.
200. Pickard B.S., Malloy M.P., Christoforou A., Thomson P.A., Evans K.L., Morris S.W., Hampson M., Porteous D.J., Blackwood D.H., Muir W.J. Cytogenetic and genetic evidence supports a role for the kainate-type glutamate receptor gene, GRIK4, in schizophrenia and bipolar disorder. Mol. Psychiatry 2006, 11:847-857.
201. Pickard B.S., Knight H.M., Hamilton R.S., Soares D.C., Walker R., Boyd J.K., Machell J., Mssaclean A., McGhee K.A., Condie A., Porteous D.J., St Clair D., Davis I., Blackwood D.H., Muir W.J. A common variant in the 3'UTR of the GRIK4 glutamate receptor gene affects transcript abundance and protects against bipolar disorder. Proc. Natl. Acad. Sci. U.S.A. 2008, 105:14940-14945.
202. Platt S. The role of glutamate in central nervous system health and disease: a review. Vet. J. 2005, 278-286.
203. Porter R.H.P., Eastwood S.L., Harrison P.J. Distribution of kainate receptor subunit mRNAs in human hippocampus, neocortex and cerebellum, and bilateral reduction of hippocampal GluR6 and KA2 transcripts in schizophrenia. Brain Res. 1997, 751:217-231.
204. Prata D., Breen G., Osborne S., Munro J., St Clair D., Collier D. Association of DAO and G72(DAOA)/G30 genes with bipolar affective disorder. Am. J. Med. Genet. B Neuropsychiatr. Genet. 2008, 147B:914-917.
205. Pulver A.E., Karayiorgou M., Wolyniec P.S., Lasseter V.K., Kasch L., Nestadt G., Antonarakis S., Housman D., Kazazian H.H., Meyers D., et al. Sequential strategy to identify a susceptibility gene for schizophrenia: report of potential linkage on chromosome 22q12-q13.1: Part 1. Am. J. Med. Genet. 1994, 54:36-43.
206. Qin S., Zhao X., Pan Y., Liu J., Feng G., Fu J., Bao J., Zhang Z., He L. An association study of the N-methyl-D-aspartate receptor NR1 subunit gene (GRIN1) and NR2B subunit gene (GRIN2B) in schizophrenia with universal DNA microarray. Eur. J. Hum. Genet. 2005, 13:807-814.
207. Ramoz N., Reichert J.G., Smith C.J., Silverman J.M., Bespalova I.N., Davis K.L., Buxbaum J.D. Linkage and association of the mitochondrial aspartate/glutamate carrier SLC25A12 gene with autism. Am. J. Psychiatry. 2004, 161:662-669.
208. Rice S.R., Niu N., Berman D.B., Heston L.L., Sobell J.L. Identification of single nucleotide polymorphisms (SNPs) and other sequence changes and estimation of nucleotide diversity in coding and flanking regions of the NMDAR1 receptor gene in schizophrenic patients. Mol. Psychiatry 2001, 6:274-284.
209. Riederer P., Lange K.W., Kornhuber J., Jellinger K. Glutamate receptor antagonism: neurotoxicity, anti-akinetic effects, and psychosis. J. Neural Transm. Suppl. 1991, 34:203-210.
210. Ring H.A., Reynolds E.H. Vigabatrin and behaviour disturbance. Lancet 1990, 335:970.
211. Rothstein J., Dykes-Hoberg M., Pardo C., Bristol L.A., Jin L., Kuncl R., Kanai Y., Hediger M., Wang Y., Schielke J., Welty D. Knockout of glutamate transporters reveals a major role for astroglial transport in excitotoxicity and clearance of glutamate. Neuron 1996, 675-686.
212. Sacchi S., Bernasconi M., Martineau M., Mothet J.P., Ruzzene M., Pilone M.S., Pollegioni L., Molla G. pLG72 modulates intracellular D-serine levels through its interaction with D-amino acid oxidase: effect on SZ susceptibility. J. Biol. Chem. 2008 Aug 8, 283(32):22244-22256.
213. Sakurai K., Toru M., Yamakawa-Kobayashi K., Arinami T. Mutation analysis of the N-methyl-D-aspartate receptor NR1 subunit gene (GRIN1) in schizophrenia. Neurosci. Lett. 2000, 296:168-170.
214. Sander J.W., Hart Y.M., Trimble M.R., Shorvon S.D. Vigabatrin and psychosis. J. Neurol. Neurosurg. Psychiatry 1991, 54:435-439.
215. Sartorius L.J., Weinberger D.R., Hyde T.M., Harrison P.J., Kleinman J.E., Lipska B.K. Expression of a GRM3 splice variant is increased in the dorsolateral prefrontal cortex of individuals carrying a schizophrenia risk SNP. Neuropsychopharmacology 2008, 33:2626-2634.
216. Scarr E., Pavey G., Sundram S., MacKinnon A., Dean B. Decreased hippocampal NMDA, but not kainate or AMPA receptors in bipolar disorder. Bipolar Disorders 2003, 5:257-264.
217. Schiffer H.H. Glutamate receptor genes: susceptibility factors in schizophrenia and depressive disorders?. Mol. Neurobiol. 2002, 25:191-212.
218. Schiffer H.H., Heinemann S.F. Association of the human kainate receptor GluR7 gene (GRIK3) with recurrent major depressive disorder. Am. J. Med. Genet. B Neuropsychiatr. Genet. 2007, 144B:20-26.
219. Schoepp D.D., Wright R.A., Levine L.R., Gaydos B., Potter W.Z. LY354740, an mGlu2/3 receptor agonist as a novel approach to treat anxiety/stress. Stress 2003, 6:189-197.
220. Schumacher J., Abon Jamra R., Freudenberg J., Becker T., Ohlraun S., Otte A.C.J., Tullius M., Kovalenko S., Van Den Bogaert A., Maier W., Rietschel M., Propping P., Nothen M.M., Cichon S. Examination of G72 and D-amino-acid oxidase as genetic risk factors for schizophrenia and bipolar affective disorder. Mol. Psychiatry 2004, 9:203-207.
221. Schwab S.G., Plummer C., Albus M., Borrmann-Hassenbach M., Lerer B., Trixler M., Maier W., Wildenauer D.B. DNA sequence variants in the metabotropic glutamate receptor 3 and risk to schizophrenia: an association study. Psychiatr. Genet. 2008, 18:25-30.
222. Scolnick E.M., Petryshen T., Sklar P. Schizophrenia: do the genetics and neurobiology of neuregulin provide a pathogenesis model?. Harv. Rev. Psychiatry 2006, 14:64-77.
223. Seeman P., Battaglia G., Corti C., Corsi M., Bruno V. Glutamate receptor mGlu2 and mGlu3 knockout striata are dopamine supersensitive, with elevated D2(High) receptors and marked supersensitivity to the dopamine agonist (+)PHNO. Synapse 2009, 63:247-251.
224. Segurado R., Conroy J., Meally E., Fitzgerald M., Gill M., Gallagher L. Confirmation of association between autism and the mitochondrial aspartate/glutamate carrier SLC25A12 gene on chromosome 2q31. Am. J. Psychiatry. 2005, 162:2182-2184.
225. Sheng M. Molecular organization of the postsynaptic specialization. Proc. Natl. Acad. Sci. USA 2001, 98:7058-7061.
226. Shi J., Badner J.A., Gershon E.S., Chunyu L., Willour V.L., Potash J.B. Further evidence for an association of G72/G30 with schizophrenia in Chinese. Schizophr. Res. 2009, 107:324-326.
227. Shi J., Badner J.A., Hattori E., Potash J.B., Willour V.L., McMahon F.J., Gershon E.S., Liu C. Neurotransmission and bipolar disorder: a systematic family-based association study. Am. J. Med. Genet. B Neuropsychiatr. Genet. 2008, 147B:1270-1277.
228. Shi S., Hayashi Y., Petralia R., Zaman S., Wenthold R., Svoboda K. Rapid spine delivery and redistribution of AMPA receptors after synaptic NMDA receptor activation. Science 1999, 1755-1757.
229. Shibata H., Shibata A., Ninomiya H., Tashiro N., Fukumaki Y. Association study of polymorphisms in the GluR6 kainate receptor gene (GRIK2) with schizophrenia. Psychiatry Res. 2002, 113:59-67.
230. Shibata H., Aramaki T., Sakai M., Ninomiya H., Tashiro N., Iwata N., Ozaki N., Fukumaki Y. Association study of polymorphisms in the GluR7, KA1 and KA2 kainate receptor genes (GRIK3, GRIK4, GRIK5) with schizophrenia. Psychiatry Res. 2006, 141:39-51.
231. Shibata H., Tani A., Chikuhara T., Kikuta R., Sakai M., Ninomiya H., Tashiro N., Iwata N., Ozaki N., Fukumaki Y. Association study of polymorphisms in the group III metabotropic glutamate receptor genes, GRM4 and GRM7, with schizophrenia. Psychiatry Res. 2009, 167:88-96.
232. Shin H.D., Park B.L., Kim E.M., Lee S.O., Cheong H.S., Lee C.H., Kim S.G., Sohn J.W., Park C.S., Kim J.W., Kim B.H., Kim I.Y., Choi I.G., Woo S.I. Association analysis of G72/G30 polymorphisms with schizophrenia in the Korean population. Schizophr. Res. 2007, 96:119-124.
233. Simeone T.A., Donevan S.D., Rho J.M. Molecular biology and ontogeny of gamma-aminobutyric acid (GABA) receptors in the mammalian central nervous system. J. Child Neurol. 2003, 18:39-48. discussion 49.
234. Simmons D.A., Rex C.S., Palmer L., Pandyarajan V., Fedulov V., Gall C.M., Lynch G. Up-regulating BDNF with an ampakine rescues synaptic plasticity and memory in Huntington's disease knockin mice. Proc. Natl. Acad. Sci. U.S.A. 2009 Mar 24, 106(12):4906-4911.
235. Sivilotti L., Nistri A. GABA receptor mechanisms in the central nervous system. Prog. Neurobiol. 1991, 36:35-92.
236. Sklar P., Pato M.T., Kirby A., Petryshen T.L., Medeiros H., Carvalho C., Macedo A., Dourado A., Coelho I., Valente J., Soares M.J., Ferreira C.P., Lei M., Verner A., Hudson T.J., Morley C.P., Kennedy J.L., Azevedo M.H., Lander E., Daly M.J., Pato C.N. Genome-wide scan in Portuguese Island families identifies 5q31-5q35 as a susceptibility locus for schizophrenia and psychosis. Mol. Psychiatry 2004, 9:213-218.
237. Smith R.E., Haroutunian V., Davis K.L., Meador-Woodruff J.H. Expression of excitatory amino acid transporter transcripts in the thalamus of subjects with schizophrenia. Am. J. Psychiatry 2001, 158:1393-1399.
238. Sodhi M., Wood K.H., Meador-Woodruff J. Role of glutamate in schizophrenia: integrating excitatory avenues of research. Expert Rev. Neurother. 2008, 8:1389-1406.
239. Sokolov B.P. Expression of NMDAR1, GluR1, GluR7, and KA1 glutamate receptor mRNAs is decreased in frontal cortex of 'neuroleptic-free' schizophrenics: evidence on reversible up-regulation by typical neuroleptics. J. Neurochem. 1998, 71:2454-2464.
240. Song I., Huganir R.L. Regulation of AMPA receptors during synaptic plasticity. Trends Neurosci. 2002, 25:578-588.
241. Squires R.F., Saederup E. A review of evidence for GABergic predominance/glutamatergic deficit as a common etiological factor in both schizophrenia and affective psychoses: more support for a continuum hypothesis of " functional" psychosis. Neurochem. Res. 1991, 16:1099-1111.
242. Stine O.C., Xu J., Koskela R., McMahon F.J., Gschwend M., Friddle C., Clark C.D., McInnis M.G., Simpson S.G., Breschel T.S., Vishio E., Riskin K., Feilotter H., Chen E., Shen S., Folstein S., Meyers D.A., Botstein D., Marr T.G., DePaulo J.R. Evidence for linkage of bipolar disorder to chromosome 18 with a parent-of-origin effect. Am. J. Hum. Genet. 1995, 57:1384-1394.
243. Straub R.E., MacLean C.J., Martin R.B., Ma Y., Myakishev M.V., Harris-Kerr C., Webb B.T., O'Neill F.A., Walsh D., Kendler K.S. A schizophrenia locus may be located in region 10p15-p11. Am. J. Med. Genet. 1998, 81:296-301.
244. Straub R.E., Lipska B.K., Egan M.F., Goldberg T.E., Callicott J.H., Mayhew M.B., Vakkalanka R.K., Kolachana B.S., Kleinman J.E., Weinberger D.R. Allelic variation in GAD1 (GAD67) is associated with schizophrenia and influences cortical function and gene expression. Mol. Psychiatry 2007, 12:854-869.
245. Sucher N.J., Akbarian S., Chi C.L., Leclerc C.L., Awobuluyi M., Deitcher D.L., Wu M.K., Yuan J.P., Jones E.G., Lipton S.A. Developmental and regional expression pattern of a novel NMDA receptor-like subunit (NMDAR-L) in the rodent brain. J. Neurosci. 1995, 15:6509-6520.
246. Takaki H., Kikuta R., Shibata H., Ninomiya H., Tashiro N., Fukumaki Y. Positive associations of polymorphisms in the metabotropic glutamate receptor type 8 gene (GRM8) with schizophrenia. Am. J. Med. Genet. B Neuropsychiatr. Genet. 2004, 128B:6-14.
247. Tamminga C.A., Crayton J.W., Chase T.N. Muscimol: GABA agonist therapy in schizophrenia. Am. J. Psychiatry 1978, 135:746-747.
248. Tan H.Y., Chen Q., Sust S., Buckholtz J.W., Meyers J.D., Egan M.F., Mattay V.S., Meyer-Lindenberg A., Weinberger D.R., Callicott J.H. Epistasis between catechol-O-methyltransferase and type II metabotropic glutamate receptor 3 genes on working memory brain function. Proc. Natl. Acad. Sci. U.S.A. 2007, 104:12536-12541.
249. Tanaka Y., Obata T., Sassa T., Yoshitome E., Asai Y., Ikehira H., Suhara T., Okubo Y., Nishikawa T. Quantitative magnetic resonance spectroscopy of schizophrenia: relationship between decreased N-acetylaspartate and frontal lobe dysfunction. Psychiatry Clin. Neurosci. 2006, 60:365-372.
250. Tang J., Chen X., Xu X., Wu R., Zhao J., Hu Z., Xia K. Significant linkage and association between a functional (GT)n polymorphism in promoter of the N-methyl-D-aspartate receptor subunit gene (GRIN2A) and schizophrenia. Neurosci. Lett. 2006, 409:80-82.
251. Tochigi M., Suga M., Ohashi J., Otowa T., Yamasue H., Kasai K., Kato T., Okazaki Y., Kato N., Sasaki T. No association between the metabotropic glutamate receptor type 3 gene (GRM3) and schizophrenia in a Japanese population. Schizophr. Res. 2006, 88:260-264.
252. Tsai G., Yang P., Chung L.C., Lange N., Coyle J.T. D-serine added to antipsychotics for the treatment of schizophrenia. Biol. Psychiatry 1998 Dec 1, 44(11):1081-1089.
253. Udalova I.A., Richardson A., Denys A., Smith C., Ackerman H., Foxwell B., Kwiatkowski D. Functional consequences of a polymorphism affecting NF-κB p50-p50 binding to the TNF promoter region. Mol. Cell. Biol. 2000, 20:9113-9119.
254. Van Den Bogaert A., Del-Favero J., Van Broeckhoven C. Major affective disorders and schizophrenia: a common molecular signature?. Hum. Mutat. 2006, 27:833-853.
255. Verrall L., Walker M., Rawlings N., Benzel I., Kew J.N.C., Harrison P.J., Burnet P.W.J. D-Amino acid oxidase and serine racemase in human brain: normal distribution and altered expression in schizophrenia. Eur. J. Neurosci. 2007, 26:1657-1669.
256. Walsh T., McClellan J.M., McCarthy S.E., Addington A.M., Pierce S.B., Cooper G.M., Nord A.S., Kusenda M., Malhotra D., Bhandari A., Stray S.M., Rippey C.F., Roccanova P., Makarov V., Lakshmi B., Findling R.L., Sikich L., Stromberg T., Merriman B., Gogtay N., Butler P., Eckstrand K., Noory L., Gochman P., Long R., Chen Z., Davis S., Baker C., Eichler E.E., Meltze Rare structural variants disrupt multiple genes in neurodevelopmental pathways in schizophrenia. Science 2008, 320:539-543.
257. Wang X., He G., Gu N., Yang J., Tang J., Chen Q., Liu X., Shen Y., Qian X., Lin W., Duan Y., Feng G., He L. Association of G72/G30 with schizophrenia in the Chinese population. Biochem. Biophys. Res. Commun. 2004, 319:1281-1286.
258. Watis L., Chen S.H., Chua H.C., Chong S.A., Sim K. Glutamatergic abnormalities of the thalamus in schizophrenia: a systematic review. J. Neural Transm. 2008, 115:493-511.
259. Wiedholz L.M., Owens W.A., Horton R.E., Feyder M., Karlsson R.M., Hefner K., Sprengel R., Celikel T., Daws L.C., Holmes A. Mice lacking the AMPA GluR1 receptor exhibit striatal hyperdopaminergia and/'schizophrenia-related/' behaviors. Mol. Psychiatry 2007, 13:631-640.
260. Williams N.M., Bowen T., Spurlock G., Norton N., Williams H.J., Hoogendoorn B., Owen M.J., O'Donovan M.C. Determination of the genomic structure and mutation screening in schizophrenic individuals for five subunits of the N-methyl-D-aspartate glutamate receptor. Mol. Psychiatry 2002, 7:508-514.
261. Wilson G.M., Flibotte S., Chopra V., Melnyk B.L., Honer W.G., Holt R.A. DNA copy-number analysis in bipolar disorder and schizophrenia reveals aberrations in genes involved in glutamate signaling. Hum. Mol. Genet. 2006, 15:743-749.
262. Wood L.S., Pickering E.H., Dechairo B.M. Significant support for DAO as a schizophrenia susceptibility locus: examination of five genes putatively associated with schizophrenia. Biol. Psychiatry 2007, 61:1195-1199.
263. Yue W., Liu Z., Kang G., Yan J., Tang F., Ruan Y., Zhang J., Zhang D. Association of G72/G30 polymorphisms with early-onset and male schizophrenia. Neuroreport 2006, 17:1899-1902.
264. Yue W., Kang G., Zhang Y., Qu M., Tang F., Han Y., Ruan Y., Lu T., Zhang J., Zhang D. Association of DAOA polymorphisms with schizophrenia and clinical symptoms or therapeutic effects. Neurosci. Lett. 2007, 416:96-100.
265. Zhang B., Yuan Y., Jia Y., Yu X., Xu Q., Shen Y. An association study between polymorphisms in five genes in glutamate and GABA pathway and paranoid schizophrenia. Eur. Psychiatry 2005, 20:45-49.
266. Zhao X., Li H., Shi Y., Tang R., Chen W., Liu J., Feng G., Shi J., Yan L., Liu H., He L. Significant association between the genetic variations in the 5′ end of the N-methyl-D-aspartate receptor subunit gene GRIN1 and schizophrenia. Biol. Psychiatry 2006, 59:747-753.
267. Zhao X., Qin S., Shi Y., Zhang A., Zhang J., Bian L., Wan C., Feng G., Gu N., Zhang G., He G., He L. Systematic study of association of four GABAergic genes: glutamic acid decarboxylase 1 gene, glutamic acid decarboxylase 2 gene, GABA(B) receptor 1 gene and GABA(A) receptor subunit beta2 gene, with schizophrenia using a universal DNA microarray. Schizophr. Res. 2007, 93:374-384.
268. Zou F., Li C., Duan S., Zheng Y., Gu N., Feng G., Xing Y., Shi J., He L. A family-based study of the association between the G72/G30 genes and schizophrenia in the Chinese population. Schizophr. Res. 2005, 73:257-261.